Quintrio
Home

IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES

Intellia Therapeutics, Inc

NTLA

Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.

Last trade $9.97
Day change +$0.11 (+1.12%)
Day range $9.69 – $10.22
Volume 4,093,945
Market cap $1.38B

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$1.38B
Price / earnings
—
Price / book
2.26×
Price / sales
26.17×
EV / sales
24.61×
EV / EBITDA
-3.06×

Profitability

Earnings per share
-$3.04
Return on assets
-47.21%
Return on equity
-69.51%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0.12×
Current ratio
6.31×
Quick ratio
6.31×
Cash ratio
1.94×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$358.08M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for NTLA, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$7.16M$7.66M$15.05M$23.02M$13.78M$14.25M$16.63M$12.87M
Cost of revenue$0$0$0$0$0$0$0$0
Gross profit$7.16M$7.66M$15.05M$23.02M$13.78M$14.25M$16.63M$12.87M
Selling, general and administrative$46.14M$37.82M$34.84M$33.08M$30.51M$27.21M$29.01M$32.44M
Research and development$83.35M$82.6M$80.74M$88.65M$94.75M$97.04M$108.43M$116.88M
Total operating expenses$129.49M$120.42M$115.58M$121.73M$125.26M$124.24M$137.43M$149.32M
Operating income-$122.33M-$112.76M-$100.53M-$98.71M-$111.48M-$110M-$120.81M-$136.45M
Interest expense-$611K$0$0$0$0$0$0$0
Income before taxes-$127.49M-$106.63M-$96.23M-$95.79M-$101.32M-$101.26M-$114.33M-$128.9M
Income taxes$0$0$0$0$0$0$0$0
Net income-$127.49M-$106.63M-$96.23M-$95.79M-$101.32M-$101.26M-$114.33M-$128.9M
Net income attributable to common shareholders-$127.49M-$106.63M-$96.23M-$95.79M-$101.32M-$101.26M-$114.33M-$128.9M
EBITDA-$120.4M-$110.68M-$98.33M-$96.33M-$109.06M-$107.52M-$118.31M-$133.88M
Basic earnings per share-$0.91-$0.80-$0.81-$0.83-$0.92-$0.98-$1.10-$1.26
Diluted earnings per share-$0.91-$0.80-$0.81-$0.83-$0.92-$0.98-$1.10-$1.26

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

Intellia Therapeutics Presents Additional Positive Clinical and Patient-Reported Data for Lonvoguran Ziclumeran (lonvo-z) at ACAAI 2026

Intellia Therapeutics announced positive clinical data for lonvo-z, its one-time CRISPR gene editing treatment for hereditary angioedema (HAE), presented at ACAAI 2026. Key findings include an 81% reduction in monthly attack rates for patients previously on long-term prophylaxis, with 100% of patients becoming prophylaxis-free. Patient interviews showed 96% described lonvo-z as optimal therapy. The FDA accepted the BLA with Priority Review and a PDUFA target action date of March 10, 2027.

GlobeNewswire Inc.

Intellia Therapeutics Announces Upcoming Lonvoguran Ziclumeran (Lonvo-z) Investor Event and Seven Presentations at ACAAI 2026

Intellia Therapeutics announced seven presentations at the ACAAI 2026 Annual Scientific Meeting featuring four-year follow-up data on lonvo-z, a one-time CRISPR gene editing treatment for hereditary angioedema (HAE). The company will host an investor webcast on November 12, 2026, to discuss the presentations and preparations for the planned commercial launch of lonvo-z. The FDA accepted the BLA for lonvo-z in September 2026 with a Priority Review and PDUFA target action date of March 10, 2027.

Zacks Investment Research

Biogen Inc. (BIIB) Tops Q3 Earnings and Revenue Estimates

Biogen Inc. reported Q3 2026 earnings of $2.62 per share, beating consensus estimates by 27.18%, with revenues of $2.8 billion exceeding expectations by 8.06%. The stock has gained 43.6% year-to-date, outperforming the S&P 500. However, the company received a Zacks Rank #3 (Hold) rating due to mixed estimate revisions, suggesting near-term performance in line with the market. Intellia Therapeutics is expected to report a quarterly loss of $0.82 per share with declining revenues.

Zacks Investment Research

4 Biotech Stocks With Promising Late-Stage Drug Pipelines to Watch Now

Four biotech companies with advanced drug pipelines present potential investment opportunities as their experimental treatments progress through late-stage development and regulatory review. BridgeBio Pharma has three drug candidates under FDA review with decisions expected through May 2027. Intellia Therapeutics' gene-editing therapy lonvo-z showed 87% reduction in hereditary angioedema attacks. Biogen expects pivotal study results through 2027, while Viking Therapeutics advances obesity treatments in phase III trials. Success depends on regulatory approvals, clinical efficacy, and competitive market positioning.

Zacks Investment Research

Intellia Therapeutics (NTLA) Soars 7.6%: Is Further Upside Left in the Stock?

Intellia Therapeutics shares rallied 7.6% following FDA acceptance of its CRISPR-based HAE treatment under Priority Review with a March 2027 decision date, and a $400 million debt facility secured in September. However, the stock carries a Hold rating as earnings estimate revisions remain unchanged, and the company faces declining revenues and quarterly losses.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.